BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1186@pharmaconomics
DTSTAMP:20260707T034813Z
DTSTART;VALUE=DATE:20260429
DTEND;VALUE=DATE:20260430
SUMMARY:GSK Phase 2 — Mo-Rez ADC
DESCRIPTION:Phase 2 trial results for Mo-Rez ADC in difficult-to-treat endometrial and ovarian cancer are due Apr 29\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1131399/000165495426004051/a2755c.htm\n\nTrack it: https://www.pharmaconomics.com/e/1186
URL:https://www.pharmaconomics.com/e/1186
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:GSK catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR